Adebrelimab + Oxaliplatin + Capecitabine + Paclitaxel + Cisplatin

This is a combination regimen consisting of five anti-cancer agents: - **Adebrelimab** is a monoclonal antibody targeting PD-L1 (programmed death-ligand 1), acting as an immune checkpoint inhibitor to enhance the immune system's ability to recognize and destroy cancer cells. - **Oxaliplatin** is a platinum-based chemotherapy that causes DNA crosslinking and inhibits DNA synthesis in rapidly dividing cells. - **Capecitabine** is an oral prodrug converted to 5-fluorouracil (5-FU) in the body; it interferes with DNA synthesis by inhibiting thymidylate synthase. - **Paclitaxel** is a taxane-class chemotherapy that stabilizes microtubules and prevents cell division by inhibiting mitosis[5]. - **Cisplatin** is another platinum-based agent that forms DNA adducts leading to apoptosis in cancer cells[1][2][3]. This multi-agent regimen combines immunotherapy with several chemotherapies commonly used for gastrointestinal cancers (such as gastric or colorectal cancer), gynecologic cancers (such as cervical or ovarian cancer), and other solid tumors. The combination aims for synergistic anti-tumor effects through both direct cytotoxicity and immune modulation.

Other names

XELOXCAPOX